Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rafal Iskanderian"'
Autor:
Mahmoud Al-Masri, Tawfiq Al-Shobaki, Hani Al-Najjar, Rafal Iskanderian, Enas Younis, Niveen Abdallah, Abdelghani Tbakhi, Hussam Haddad, Mohammad Al-Masri, Zeinab Obeid, Awad Jarrar
Publikováno v:
Endocrine Connections, Vol 10, Iss 12, Pp 1531-1537 (2021)
Purpose: This study focuses on the oncologic influence of BRAF V600E mutations in a cohort of Middle Eastern papillary thyroid carcinoma (PTC) patients treated at a single centre. We tested the association of BRAF V600E mutation with papillary thyroi
Externí odkaz:
https://doaj.org/article/8a7d899516f041bc92d000f93d53785a
Autor:
Awad Jarrar, Enas Younis, Rafal Iskanderian, Tawfiq Al-Shobaki, Abdelghani Tbakhi, Mahmoud Al-Masri, Hussam Haddad, Hani Al-Najjar, Niveen Abdallah, Zeinab Obeid, Mohammad AlMasri
Publikováno v:
Endocrine Connections
Endocrine Connections, Vol 10, Iss 12, Pp 1531-1537 (2021)
Endocrine Connections, Vol 10, Iss 12, Pp 1531-1537 (2021)
Purpose This study focuses on the oncologic influence of BRAF V600E mutations in a cohort of Middle Eastern papillary thyroid carcinoma (PTC) patients treated at a single centre. We tested the association of BRAF V600E mutation with papillary thyroid
Autor:
Mahmoud Al-Masri, Tawfiq Al-Shobaki, Hani Al-Najjar, Rafal Iskanderian, Enas Younis, Niveen Abdallah, Abdelghani Tbakhi, Hussam Haddad, Awad Jarrar, Mohammad Al-Masri
Introduction BRAF V600E is one of the most common mutations in Papillary Thyroid Cancer (PTC). Its clinical correlation has been extensively studied with contradictory results. The aim of this study is to evaluate the oncological impact of BRAF V600E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1355b1177deff13bb2dd77d7539ba526
https://doi.org/10.21203/rs.3.rs-119519/v1
https://doi.org/10.21203/rs.3.rs-119519/v1